LDL/ApoB Ratio (Atherogenic Risk) Calculator

Clinical calculation support · Verify results before clinical use

Calculate the LDL-C/ApoB Ratio

Enter both measurements in mg/dL. The result is a descriptive ratio, not a validated standalone cardiovascular risk score.

Use the LDL-C result reported by the laboratory.

ApoB reflects the number of circulating atherogenic lipoprotein particles.

Reset calculator

Clinical context

LDL cholesterol (LDL-C) measures the cholesterol mass carried in LDL particles. Apolipoprotein B (ApoB) reflects the number of atherogenic lipoprotein particles because each LDL, VLDL, and lipoprotein(a) particle carries one ApoB molecule.

The ratio can be calculated mathematically, but a calculated value should not be mistaken for a validated clinical risk category. The original version of this tool used thresholds below 1.2, from 1.2 to 1.5, and above 1.5. These thresholds are not retained as risk labels because the reviewed guideline and consensus sources support measuring ApoB and assessing LDL-C/ApoB discordance, but do not establish those universal ratio cutoffs.

Practical interpretation

  • Assess ApoB as a marker of atherogenic particle burden, particularly when LDL-C and the broader clinical picture appear discordant.
  • Use established clinical risk assessment, LDL-C/non-HDL-C levels, ApoB where appropriate, and applicable guideline recommendations to guide treatment.
  • Do not interpret a higher or lower ratio as proof of a particular LDL particle size or as a stand-alone estimate of cardiovascular risk.

References

2026 ACC/AHA Dyslipidemia Guideline 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Supports ApoB measurement in selected patients and notes the role of ApoB when LDL-C and particle burden are discordant. Official guideline.
Wilson PWF, et al. / National Lipid Association Expert Clinical Consensus Role of apolipoprotein B in the clinical management of cardiovascular risk in adults. Journal of Clinical Lipidology. 2024;18(5):e647–e663. doi:10.1016/j.jacl.2024.08.013. PubMed.
Sniderman AD, et al. Discordance of LDL cholesterol with apolipoprotein B and cardiovascular risk. Current Opinion in Lipidology. 2003;14(4):377–384. doi:10.1097/01.mol.0000086423.29012.64. This supports the clinical relevance of discordance; it does not by itself validate the original ratio cutoffs.
Berneis KK, Krauss RM. Metabolic origins and clinical significance of LDL heterogeneity. Journal of Lipid Research. 2002;43(9):1363–1379. doi:10.1194/jlr.R200015-JLR200. Background on LDL heterogeneity, not validation of the original ratio thresholds.
Clinical disclaimer: This calculator performs a mathematical calculation and is intended for educational and clinical-support purposes. It does not diagnose dyslipidemia, calculate absolute ASCVD risk, or replace clinical judgement. Confirm units and laboratory results, and interpret findings in the context of the patient's history, comorbidities, and current guidelines.